V116517

V116517 is a potent and orally active small molecule antagonist of the transient receptor potential vanilloid 1 (TRPV1) channel. It was initially developed by Purdue Pharma for the treatment of pain conditions. The drug has been investigated in clinical trials for its analgesic efficacy and safety in subjects with moderate to severe chronic pain due to postherpetic neuralgia (PHN), as well as other indications such as arthralgia and osteoarthritis of the knee. By antagonizing TRPV1 channels—also known as vanilloid receptors—V116517 inhibits capsaicin-induced activation and may reduce pain signaling associated with neuropathic and inflammatory conditions[1][2][3][4].

Other names

4-(3-chloro-5-(1,2-dihydroxyethyl)-2-pyridyl)-N-(5-(trifluoromethyl)-2-pyridyl)-3,6-dihydro-2H-pyridine-1-carboxamide